Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №9 (2024) > Obesity and reproductive health: “nocturne” to modern comorbidity

Obesity and reproductive health: “nocturne” to modern comorbidity

Mekan R. Orazov , Viktor E. Radzinsky , Vera E. Balan , Evgeny D. Dolgov

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Modern trends of human lifestyle changes contribute to the unparalleled increase in the incidence of some occupational diseases. And, despite the development of modern technologies and such a pronounced leap in social development, obesity remains an unresolved issue of mankind. Today, obesity represents an overwhelming problem that needs to be solved immediately and covers many medical specialties, including gynecology. In this regard, the paper is aimed to consider epidemiological features of obesity as a global issue and report the key touchpoints with modern gynecology and key approaches to clinical management of patients of this cohort.
Keywords: obesity, endometrial cancer, drug therapy, liraglutide, semaglutide.

About the Author

Mekan R. Orazov 1 , Viktor E. Radzinsky 1 , Vera E. Balan 2 , Evgeny D. Dolgov 1

1 Patrice Lumumba People’s Friendship University of Russia (RUDN University), Moscow, Russia

2 Vladimirsky Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia

References

1. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: WHO, 1997.
2. Neel JV. Diabetes mellitus: a «thrifty» genotype rendered detrimental by «progress»? Am J Hum Genet 1962;14(4):353-62.
3. Song S. Assessing the impact of in utero exposure to famine on fecundity: evidence from the 1959–1961 famine in China. Popul Stud (Camb) 2013;67(3):293-308. DOI: 10.1080/00324728.2013.774045
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010;303(3):235-41. DOI: 10.1001/jama.2009.2014
5. Singh GK, Siahpush M, Hiatt RA, Timsina LR. Dramatic increases in obesity and overweight prevalence and body mass index among ethnic-immigrant and social class groups in the United States, 1976–2008.
J Community Health 2011;36(1):94-110. DOI: 10.1007/s10900-010-9287-9
6. URL: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight
7. Salerno PR et al. County-level socio-environmental factors and obesity prevalence in the United States. Diabetes, Obesity and Metabolism 2024;26(5):1766-74.
8. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 populationrepresentative studies with 222 million children, adolescents, and adults. Lancet 2024.
9. World Health Organization. Geneva: WHO, 2022.
10. Tahergorabi Z, Khazaei M, Moodi M, Chamani E. From obesity to cancer: a review on proposed mechanisms. Cell biochemistry and function 2016;34(8):533-45.
11. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74(1):12-49. DOI: 10.3322/caac.21820
12. Tzenios N. Obesity as a Risk Factor for Different Types of Cancer. EPRA International Journal of Research and Development (IJRD) 2023;8(2):97-100.
13. Оразов М.Р., Радзинский В.Е., Хамошина М.Б. и др. Metabesity – патогенетические основы и возможности предикции. Гинекология. 2023;25(4):416-23. DOI: 10.26442/20795696.2023.4.20252
Orazov M.R., Radzinsky V.E., Khamoshina M.B. et al. Metabesity – pathogenetic foundations and possibilities of prediction. Gynecology. 2023;25(4):416-23. DOI: 10.26442/20795696.2023.4.20252 (in Russian).
14. Nutter S, Eggerichs LA, Nagpal TS et al. Changing the global obesity narrative to recognize and reduce weight stigma: a position statement from the World Obesity Federation. Obesity Reviews 2024;25(1):e13642.
15. Emmer C, Bosnjak M, Mata J. The association between weight stigma and mental health: a meta-analysis. Obes Rev 2020; 21(1):e12935. DOI: 10.1111/obr.12935
16. Daly M, Robinson E, Sutin AR. Perceived overweight and suicidality among US adolescents from 1999 to 2017. Int J Obes (Lond) 2020;44(10):2075-9. DOI: 10.1038/s41366-020-0620-9
17. Wu YK, Berry DC. Impact of weight stigma on physiological and psychological health outcomes for overweight and obese adults: a systematic review. J Adv Nurs 2018;74(5):1030-42. DOI: 10.1111/jan.13511
18. Pearl RL, Puhl RM. Weight bias internalization and health: a systematic review. Obes Rev 2018;19(8):1141-63. DOI: 10.1111/obr.12701
19. Tomiyama AJ, Epel ES, McClatchey TM et al. Associations of weight stigma with cortisol and oxidative stress independent of adiposity. Health Psychol 2014;33(8):862-7. DOI: 10.1037/hea0000107
20. Daly M, Sutin AR, Robinson E. Perceived weight discrimination mediates the prospective association between obesity and physiological dysregulation: evidence from a population-based cohort. Psychol Sci 2019;30(7):1030-9.
21. Chen EY, Bocchieri-Ricciardi LE, Munoz D et al. Depressed mood in class III obesity predicted by weight-related stigma. Obes Surg 2007;17(5):669-71. DOI: 10.1007/s11695-007-9112-4
22. Hayward LE, Vartanian LR, Pinkus RT. Weight stigma predicts poorer psychological well-being through internalized weight bias and maladaptive coping responses. Obesity 2018;26(4):755-61. DOI: 10.1002/oby. 22126
23. Chen H, Ye Y, Guo J. Impact of weight stigma on preadolescents‘ and adolescents‘ disordered eating behaviors: testing two mediation models. Soc Behav Pers 2020;48(10):10-15. DOI: 10.2224/sbp.9392
24. Chen TT, Ching BHH, Li Y, He CC, Wan R. Weight stigma from media: its associations with coping responses and health outcomes. Curr Psychol 2022;42(24):20556-69. DOI: 10.1007/s12144-022-03179-8
25. Hunger JM, Dodd DR, Smith AR. Weight-based discrimination, interpersonal needs, and suicidal ideation. Stig Health 2020;5(2):217-24. DOI: 10.1037/sah0000188
26. Kaplan LM, Apovian CM, Ard JD et al. Assessing the state of obesity care: Quality, access, guidelines, and standards. Obesity Science & Practice 2024;10(4):e765.
27. Busetto L, Dicker D, Frühbeck G et al. A new framework for the diagnosis, staging and management of obesity in adults. Nature Medicine 2024;30:1-5.
28. Di Vincenzo O, Marra M, Sacco AM et al. Bioelectrical impedance (BIA)-derived phase angle in adults with obesity: A systematic review. Clinical Nutrition 2021;40(9):5238-48.
29. Избыточная масса тела. Клинические рекомендации Минздрава России. М., 2024.
Overweight. Clinical recommendations of the Ministry of Health of Russia. Moscow, 2024 (in Russian).
30. Raza SA, Mirza AMB, Hafizullah M et al. Metabesity Guideline: A Pakistan Perspective. Journal of the Pakistan Medical Association 2021;71(5):S17-S33.
31. Ожирение. Клинические рекомендации Минздрава России. М., 2020.
Fatness. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow, 2020 (in Russian).
32. Le Roux CW et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389(10077):1399-409.
33. Valladales-Restrepo LF, Sánchez-Ramírez N, Usma-Valencia AF et al. Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity. Expert Opinion on Pharmacotherapy 2023;24(4):535-43.
34. Chowdhary A, Thirunavukarasu S, Joseph T et al. Liraglutide improves myocardial perfusion and energetics and exercise tolerance in patients with type 2 diabetes. Journal of the American College of Cardiology 2024;84(6):540-57.
35. Аметов А.С., Шохин И.Е., Рогожина Е.А. и др. Российская разработка для лекарственной независимости в эндокринологии: сравнительный анализ биоэквивалентности, безопасности и переносимости первого отечественного лираглутида. Фармация и фармакология. 2023;11(3):255-76. DOI: 10.19163/2307-9266-2023-11-3-255-276
Ametov A.S., Shokhin I.E., Rogozhina E.A. et al. Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide. Pharmacy and pharmacology. 2023;11(3):255-76. DOI: 10.19163/2307-9266-2023-11-3-255-276 (in Russian).
36. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism 2023;25(1):18-35.
37. Аметов А.С., Шохин И.Е., Рогожина Е.А. и др. Сравнительный анализ физико-химических свойств, биоэквивалентности, безопасности и переносимости отечественного семаглутида. Фармация и фармакология. 2023;11(4):324-46. DOI: 10.19163/2307-9266-2023-11-4-324-346
Ametov A.S., Shokhin I.E., Rogozhina E.A. et al. Comparative analysis of physico-chemical properties, bioequivalence, safety and tolerability of domestic semaglutide. Pharmacy and pharmacology. 2023;11(4):324-46. DOI: 10.19163/2307-9266-2023-11-4-324-346 (in Russian).
38. Wadden TA, Bailey TS, Billings LK et al; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA;325(14):1403-13. DOI: 10.1001/jama.2021.1831

For citation:Orazov M.R., Radzinsky V.E., Balan V.E., Dolgov E.D. Obesity and reproductive health: “nocturne” to modern comorbidity. Clinical review for general practice. 2024; 5 (9): 24–30 (In Russ.). DOI: 10.47407/kr2024.5.9.00474


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru